These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 2231917

  • 1. Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer.
    Rawls WH, Lamm DL, Lowe BA, Crawford ED, Sarosdy MF, Montie JE, Grossman HB, Scardino PT.
    J Urol; 1990 Dec; 144(6):1328-30. PubMed ID: 2231917
    [Abstract] [Full Text] [Related]

  • 2. Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin.
    Deresiewicz RL, Stone RM, Aster JC.
    J Urol; 1990 Dec; 144(6):1331-3; discussion 1333-4. PubMed ID: 2231918
    [Abstract] [Full Text] [Related]

  • 3. [Multiorgan failure following intravesical bacillus Calmette-Guerin administration: a case report].
    Baba Y, Ishizu K, Jojima K, Joko K, Nakamura K, Takihara H, Naito K.
    Hinyokika Kiyo; 1992 Sep; 38(9):1063-5. PubMed ID: 1414761
    [Abstract] [Full Text] [Related]

  • 4. Systemic bacillus Calmette-Guérin infection, 'BCGitis', in patients treated by intravesical bacillus Calmette-Guérin therapy for bladder cancer.
    Steg A, Leleu C, Debré B, Boccon-Gibod L, Sicard D.
    Eur Urol; 1989 Sep; 16(3):161-4. PubMed ID: 2744050
    [Abstract] [Full Text] [Related]

  • 5. Systemic bacillus-Calmette Guerin infection after transurethral administration for superficial bladder carcinoma.
    Sakamoto GD, Burden J, Fisher D.
    J Urol; 1989 Oct; 142(4):1073-4; discussion 1074-5. PubMed ID: 2795734
    [Abstract] [Full Text] [Related]

  • 6. [Granulomatous hepatitis and sepsis secondary to intravesical instillation of bacillus Calmette-Guérin].
    Garmilla-Ezquerra P, Martínez-De Las Cuevas G, Hernández-Hernández JL.
    Enferm Infecc Microbiol Clin; 2012 Dec; 30(10):656-7. PubMed ID: 22683174
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.
    Lamm DL, DeHaven JI, Shriver J, Crispen R, Grau D, Sarosdy MF.
    J Urol; 1990 Jul; 144(1):65-7. PubMed ID: 2193172
    [Abstract] [Full Text] [Related]

  • 9. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: review of complications and their treatment.
    Paterson DL, Patel A.
    Aust N Z J Surg; 1998 May; 68(5):340-4. PubMed ID: 9631906
    [Abstract] [Full Text] [Related]

  • 10. Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.
    Witjes JA, vd Meijden AP, Debruyne FM.
    Urol Int; 1990 May; 45(3):129-36. PubMed ID: 2190404
    [Abstract] [Full Text] [Related]

  • 11. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
    Hudson MA, Yuan JJ, Catalona WJ, Ratliff TL.
    J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
    [Abstract] [Full Text] [Related]

  • 12. Persistent acid-fast bacilli following intravesical bacillus Calmette-Guerin.
    Linn R, Klimberg IW, Wajsman Z.
    J Urol; 1989 May; 141(5):1197-8. PubMed ID: 2709508
    [Abstract] [Full Text] [Related]

  • 13. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.
    Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A, Debruyne FM.
    J Urol; 1992 Mar; 147(3):596-600. PubMed ID: 1538436
    [Abstract] [Full Text] [Related]

  • 14. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL, DeHaven JI, Shriver J, Sarosdy MF.
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [Abstract] [Full Text] [Related]

  • 15. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
    Haaff EO, Dresner SM, Ratliff TL, Catalona WJ.
    J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
    [Abstract] [Full Text] [Related]

  • 16. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
    Kavoussi LR, Torrence RJ, Gillen DP, Hudson MA, Haaff EO, Dresner SM, Ratliff TL, Catalona WJ.
    J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
    [Abstract] [Full Text] [Related]

  • 17. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
    Kelley DR, Ratliff TL, Catalona WJ, Shapiro A, Lage JM, Bauer WC, Haaff EO, Dresner SM.
    J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
    [Abstract] [Full Text] [Related]

  • 18. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE, Marcus MD, Myers JA, Ratliff TL, Catalona WJ.
    J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
    [Abstract] [Full Text] [Related]

  • 19. [Systemic Bacillus Calmette-Guerin sepsis manifesting as autoimmunity, 17 months after an intravesical BCG-therapy].
    Goulabchand R, Dufour S, Murez T, Broner J, Rivière S, Guilpain P, Le Quellec A.
    Med Mal Infect; 2017 Dec; 47(8):558-561. PubMed ID: 28943176
    [No Abstract] [Full Text] [Related]

  • 20. A case of granulomatous hepatitis after intravesical bacillus Calmette-Guerin administration.
    Graziano DA, Jacobs D, Lozano RG, Buck RL.
    J Urol; 1991 Oct; 146(4):1118-9. PubMed ID: 1895437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.